BioCentury | Aug 4, 2018
Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
BioCentury | Jan 27, 2018
Finance

All together now

Promising proof-of-concept data from BioCryst Pharmaceuticals Inc. and a management team from Idera Pharmaceuticals Inc. with the requisite market know-how proved the right combination for a merger of two of the industry’s longest-standing independent small...
BC Week In Review | Jan 12, 2018
Company News

Shire to split neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
BC Extra | Jan 9, 2018
Company News

Shire splits neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
BC Week In Review | Feb 9, 2017
Company News

Vancocin vancomycin news

In a federal lawsuit, the U.S. Federal Trade Commission alleged that the Shire ViroPharma Inc. subsidiary of Shire abused the Citizen's Petition process and violated antitrust laws to delay generic competition for antibiotic Vancocin vancomycin....
BC Extra | Feb 8, 2017
Company News

FTC suit alleges Shire abused FDA process

In a federal lawsuit , the U.S. Federal Trade Commission alleged that the Shire ViroPharma Inc. subsidiary of Shire plc (LSE:SHP; NASDAQ:SHPG) abused the Citizen's Petition process and violated antitrust laws to delay generic competition for...
BioCentury | Jan 18, 2016
Strategy

Shire's serial story

The most obvious benefits Shire plc expects to gain by acquiring Baxalta Inc. are a slew of new products and the cash to make subsequent acquisitions the company couldn't have made on its own. But...
BioCentury | Jan 4, 2016
Product Development

Turnabout

The firestorm over compassionate access that pushed Chimerix Inc. into studying brincidofovir in adenovirus last year already saved the life of Josh Hardy and may now prove to be the company's saving grace as well....
BC Extra | Dec 19, 2015
Company News

Soland replaces Aldag as uniQure CEO

uniQure N.V. (NASDAQ:QURE) named Dan Soland CEO to succeed Joern Aldag, who had been planning to step down as soon as a replacement could be found. Soland was VP and COO at ViroPharma Inc. , which...
BioCentury | Nov 9, 2015
Finance

HAE maker

The $10.5 billion shopping spree by Shire plc (LSE:SHP; NASDAQ:SHPG) in hereditary angioedema likely has come to an end, as the company expects it now has all the HAE products it needs. The final deal...
Items per page:
1 - 10 of 638
BioCentury | Aug 4, 2018
Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
BioCentury | Jan 27, 2018
Finance

All together now

Promising proof-of-concept data from BioCryst Pharmaceuticals Inc. and a management team from Idera Pharmaceuticals Inc. with the requisite market know-how proved the right combination for a merger of two of the industry’s longest-standing independent small...
BC Week In Review | Jan 12, 2018
Company News

Shire to split neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
BC Extra | Jan 9, 2018
Company News

Shire splits neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
BC Week In Review | Feb 9, 2017
Company News

Vancocin vancomycin news

In a federal lawsuit, the U.S. Federal Trade Commission alleged that the Shire ViroPharma Inc. subsidiary of Shire abused the Citizen's Petition process and violated antitrust laws to delay generic competition for antibiotic Vancocin vancomycin....
BC Extra | Feb 8, 2017
Company News

FTC suit alleges Shire abused FDA process

In a federal lawsuit , the U.S. Federal Trade Commission alleged that the Shire ViroPharma Inc. subsidiary of Shire plc (LSE:SHP; NASDAQ:SHPG) abused the Citizen's Petition process and violated antitrust laws to delay generic competition for...
BioCentury | Jan 18, 2016
Strategy

Shire's serial story

The most obvious benefits Shire plc expects to gain by acquiring Baxalta Inc. are a slew of new products and the cash to make subsequent acquisitions the company couldn't have made on its own. But...
BioCentury | Jan 4, 2016
Product Development

Turnabout

The firestorm over compassionate access that pushed Chimerix Inc. into studying brincidofovir in adenovirus last year already saved the life of Josh Hardy and may now prove to be the company's saving grace as well....
BC Extra | Dec 19, 2015
Company News

Soland replaces Aldag as uniQure CEO

uniQure N.V. (NASDAQ:QURE) named Dan Soland CEO to succeed Joern Aldag, who had been planning to step down as soon as a replacement could be found. Soland was VP and COO at ViroPharma Inc. , which...
BioCentury | Nov 9, 2015
Finance

HAE maker

The $10.5 billion shopping spree by Shire plc (LSE:SHP; NASDAQ:SHPG) in hereditary angioedema likely has come to an end, as the company expects it now has all the HAE products it needs. The final deal...
Items per page:
1 - 10 of 638